Patient Guide: A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 25 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06483334
Status: 🟢 Enrolling Now
Condition: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 25 locations across the country.

Top locations include:
  • • San Francisco, California
  • • Chicago, Illinois
  • • Indianapolis, Indiana
  • • And 22 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) - Join Clinical Trial NCTNCT06483334

How to Join This Clinical Trial - NCTNCT06483334

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06483334 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 25 locations. Find a study site near you:

Clinical Research Site

San Francisco, California 94158 - United States

Status: RECRUITING

Clinical Research Site

Chicago, Illinois 60637 - United States

Status: RECRUITING

Clinical Research Site

Indianapolis, Indiana 46202 - United States

Status: RECRUITING

Clinical Research Site

Boston, Massachusetts 02115 - United States

Status: RECRUITING

Clinical Research Site

St Louis, Missouri 63108 - United States

Status: RECRUITING

Clinical Research Site

New York, New York 10029 - United States

Status: RECRUITING

Clinical Research Site

Cleveland, Ohio 44195 - United States

Status: RECRUITING

Clinical Research Site

Salt Lake City, Utah 84112 - United States

Status: RECRUITING

Clinical Research Site

Ottawa, Ontario K1H 8L6 - Canada

Status: RECRUITING

Clinical Research Site

Toronto, Ontario M5G 2M9 - Canada

Status: ACTIVE_NOT_RECRUITING

And 15 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships